Treatment of 80 Patients with Turner's Syndrome with Recombinant Human Growth Hormone (YM-17798) for One Year: The Results of a Multicentric Study in Japan

6Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

A total of 80 patients with Turner's syndrome were treated with methioninefree recombinant hGH (r-hGH) for one year. Thirty-nine patients were treated with r-hGH at weekly dosage of 0.5IU/kg and forty-one were treated with 1.0 IU/kg/w by daily sc injection. Both treatment groups showed a statistically significant growth increase during the treatment from 3.7 α 1.0 to 6.0α1.1 and 7.2α1.3 (MeanαSD) cm/year, respectively. Fifty-nine percent of the patients treated with 0.5 IU/kg/w and 87.8% of the patients treated with 1.0 IU/kg/w showed a growth rate more than 2cm greater than the pretreatment values. Plasma somatomedin C levels were elevated and no remarkable advances in bone age were observed during the treatment in both treatment groups. An antibody against to hGH was observed in 6.8% of the patients. Otherwise, there were no significant changes in physical or laboratory examinations. No glucose intolerance was observed. These results indicate that hGH treatment is useful in accelerating growth velocity in patients with Turner's syndrome. © 1989, The Japan Endocrine Society. All rights reserved.

Cite

CITATION STYLE

APA

Takano, K., Shizume, K., Hibi, I., Takano, K., Shizume, K., & Hibi, I. (1989). Treatment of 80 Patients with Turner’s Syndrome with Recombinant Human Growth Hormone (YM-17798) for One Year: The Results of a Multicentric Study in Japan. Endocrinologia Japonica, 36(2), 253–260. https://doi.org/10.1507/endocrj1954.36.253

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free